Immuron Limited(IMRN)Earnings, Financials & Key Ratios
IMRN•NASDAQ
$0.82
$7M mkt cap·Price updated May 6, 2026
AboutImmuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.Show more
- Revenue$7M+48.6%
- EBITDA-$5M+8.0%
- Net Income-$5M+24.8%
- EPS (Diluted)-0.90+26.2%
- Gross Margin65.39%-3.9%
- EBITDA Margin-72.66%+38.1%
- Operating Margin-73.34%+38.0%
- Net Margin-71.58%+49.4%
- ROE-50.3%-17.2%
- ROIC-122.51%+45.5%
- Debt/Equity0.01+6.8%
- Interest Coverage-731.63+4.5%
IMRN Key Insights
Immuron Limited (IMRN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 23.7%
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IMRN Price & Volume
Immuron Limited (IMRN) stock price & volume — 10-year historical chart
Loading chart...
IMRN Growth Metrics
Immuron Limited (IMRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.94%
5 Years23.67%
3 Years111.96%
TTM61.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM25.41%
Return on Capital
10 Years-62.61%
5 Years-33.55%
3 Years-34.36%
Last Year-50.96%
IMRN Peer Comparison
Immuron Limited (IMRN) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 VXRT | 179.17M | 0.75 | 10.64 | 7.27% | 6.88% | 33.83% | 0.10 | |
 DYAI | 27.51M | 0.76 | -3.80 | 20.58% | -279.56% | -281.83% | 2.05 | |
 IBRX | 8.25B | 8.38 | -13.52 | 22.71% | -422.28% | |||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% |
Compare IMRN vs Peers
Immuron Limited (IMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMRN Income Statement
Immuron Limited (IMRN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.4M | 1.84M | 2.39M | 2.52M | 145.78K | 765.19K | 1.8M | 4.9M | 7.29M |
| Revenue Growth % | 39.47% | 31.99% | 29.55% | 5.49% | -94.21% | 424.91% | 135.85% | 171.67% | 48.63% |
| Cost of Goods Sold | 474.04K | 582.29K | 680.76K | 688.84K | 810.84K | 241.69K | 64.63K | 1.57M | 2.52M |
| COGS % of Revenue | 33.95% | 31.6% | 28.51% | 27.35% | 556.22% | 31.59% | 3.58% | 31.94% | 34.61% |
| Gross Profit | 922.16K▲ 0% | 1.26M▲ 36.7% | 1.71M▲ 35.4% | 1.83M▲ 7.2% | -665.06K▼ 136.3% | 523.5K▲ 178.7% | 1.74M▲ 232.4% | 3.34M▲ 91.8% | 4.77M▲ 42.8% |
| Gross Margin % | 66.05% | 68.4% | 71.49% | 72.65% | -456.22% | 68.41% | 96.42% | 68.06% | 65.39% |
| Gross Profit Growth % | 32.6% | 36.7% | 35.38% | 7.21% | -136.35% | 178.72% | 232.39% | 91.76% | 42.8% |
| Operating Expenses | 9.31M | 4.25M | 6.36M | 4.74M | 7.71M | 3.39M | 5.31M | 9.14M | 10.11M |
| OpEx % of Revenue | 666.9% | 230.54% | 266.53% | 188.02% | 5292.26% | 443.46% | 294.17% | 186.38% | 138.74% |
| Selling, General & Admin | 4.68M | 4.1M | 5.9M | 4.04M | 6.38M | 3.94M | 5.15M | 6.59M | 7.94M |
| SG&A % of Revenue | 335.24% | 222.44% | 247.23% | 160.47% | 4378.21% | 515.02% | 285.27% | 134.32% | 108.91% |
| Research & Development | 4.63M | 2.26M | 1.04M | 1.18M | 1.37M | 657.72K | 2.59M | 5.38M | 3.6M |
| R&D % of Revenue | 331.66% | 122.48% | 43.75% | 46.8% | 937.78% | 85.95% | 143.63% | 109.64% | 49.37% |
| Other Operating Expenses | 0 | -2.11M | -583.86K | -485.01K | -34.58K | -1.21M | -2.43M | -2.82M | -1.42M |
| Operating Income | -8.39M▲ 0% | -2.99M▲ 64.4% | -4.66M▼ 55.8% | -2.91M▲ 37.6% | -8.38M▼ 188.4% | -2.87M▲ 65.8% | -3.57M▼ 24.4% | -5.8M▼ 62.5% | -5.34M▲ 7.9% |
| Operating Margin % | -600.86% | -162.13% | -195.04% | -115.37% | -5748.48% | -375.05% | -197.75% | -118.32% | -73.34% |
| Operating Income Growth % | -1.54% | 64.38% | -55.84% | 37.6% | -188.41% | 65.75% | -24.36% | -62.55% | 7.87% |
| EBITDA | -8.38M | -2.98M | -4.65M | -2.89M | -8.37M | -2.84M | -3.52M | -5.76M | -5.29M |
| EBITDA Margin % | -600.5% | -161.86% | -194.82% | -114.63% | -5745.03% | -371.57% | -195.06% | -117.38% | -72.66% |
| EBITDA Growth % | -1.52% | 64.42% | -55.93% | 37.93% | -190.07% | 66.05% | -23.81% | -63.49% | 8% |
| D&A (Non-Cash Add-back) | 4.92K | 5.05K | 5.29K | 18.42K | 5.04K | 26.61K | 48.66K | 45.98K | 49.69K |
| EBIT | -8.39M | -3.25M | -4.71M | -3.07M | -7.96M | -3.12M | -3.41M | -5.22M | -5.36M |
| Net Interest Income | -81.27K | -22.96K | 39 | -21.63K | -4.56K | 15.6K | 106.67K | 320.18K | 128.56K |
| Interest Income | 16.1K | 1.24K | 39 | 0 | 9.2K | 21.79K | 116.32K | 327.76K | 135.87K |
| Interest Expense | 24.48K | 24.2K | 0 | 21.63K | 13.76K | 6.18K | 9.65K | 7.58K | 7.3K |
| Other Income/Expense | 1.58M | -22.96K | 39 | -21.63K | -4.56K | 15.6K | -217.67K | -1.14M | 128.56K |
| Pretax Income | -6.8M▲ 0% | -3.01M▲ 55.7% | -4.66M▼ 54.7% | -2.93M▲ 37.1% | -8.38M▼ 186.4% | -2.85M▲ 66.0% | -3.79M▼ 32.7% | -6.94M▼ 83.2% | -5.22M▲ 24.8% |
| Pretax Margin % | -487.33% | -163.38% | -195.04% | -116.23% | -5751.61% | -373.01% | -209.81% | -141.49% | -71.58% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.8M▲ 0% | -3.01M▲ 55.7% | -4.66M▼ 54.7% | -2.93M▲ 37.1% | -8.38M▼ 186.4% | -2.85M▲ 66.0% | -3.79M▼ 32.7% | -6.94M▼ 83.2% | -5.22M▲ 24.8% |
| Net Margin % | -487.33% | -163.38% | -195.04% | -116.23% | -5751.61% | -373.01% | -209.81% | -141.49% | -71.58% |
| Net Income Growth % | 3.74% | 55.75% | -54.65% | 37.14% | -186.43% | 65.96% | -32.66% | -83.2% | 24.81% |
| Net Income (Continuing) | -6.8M | -3.01M | -4.66M | -2.93M | -8.38M | -2.85M | -3.79M | -6.94M | -5.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.57▲ 0% | -0.90▲ 65.0% | -1.29▼ 43.3% | -0.66▲ 48.8% | -1.52▼ 130.3% | -0.50▲ 67.1% | -0.66▼ 32.0% | -1.22▼ 84.8% | -0.90▲ 26.2% |
| EPS Growth % | 30.54% | 64.98% | -43.33% | 48.84% | -130.3% | 67.11% | -32% | -84.85% | 26.23% |
| EPS (Basic) | -2.57 | -0.90 | -1.29 | -0.66 | -1.52 | -0.50 | -0.66 | -1.22 | -0.90 |
| Diluted Shares Outstanding | 2.65M | 3.34M | 3.62M | 4.41M | 5.53M | 5.69M | 5.69M | 5.7M | 5.77M |
| Basic Shares Outstanding | 2.65M | 3.34M | 3.62M | 4.41M | 5.53M | 5.69M | 5.69M | 5.7M | 5.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMRN Balance Sheet
Immuron Limited (IMRN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.27M | 7.05M | 6.68M | 4.41M | 25.75M | 23.67M | 20.41M | 14.73M | 9.98M |
| Cash & Short-Term Investments | 3.99M | 4.73M | 5.12M | 3.25M | 25.05M | 22.11M | 18.99M | 11.66M | 5.87M |
| Cash Only | 3.99M | 4.73M | 5.12M | 3.25M | 25.05M | 22.11M | 17.16M | 11.66M | 2.83M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.83M | 0 | 3.04M |
| Accounts Receivable | 270.13K | 492.28K | 298.93K | 327.69K | 334.71K | 662.9K | 417.42K | 1.39M | 791.39K |
| Days Sales Outstanding | 70.62 | 97.5 | 45.7 | 47.49 | 838.05 | 316.2 | 84.42 | 103.3 | 39.64 |
| Inventory | 2.34M | 497.9K | 544.34K | 797.69K | 292.53K | 326.58K | 839.97K | 1.58M | 1.77M |
| Days Inventory Outstanding | 1.8K | 312.1 | 291.85 | 422.68 | 131.68 | 493.2 | 4.74K | 369.32 | 256.52 |
| Other Current Assets | 1.67M | 1.33M | 719.29K | 33.19K | 78.26K | 0 | 0 | 0 | -1.94M |
| Total Non-Current Assets | 18.84K | 20.38K | 17.14K | 1.79M | 1.3M | 1.18M | 1.58M | 823.63K | 114.62K |
| Property, Plant & Equipment | 18.84K | 20.38K | 17.14K | 70.77K | 33.74K | 226.74K | 200.13K | 154.35K | 113.95K |
| Fixed Asset Turnover | 74.12x | 90.41x | 139.29x | 35.59x | 4.32x | 3.37x | 9.02x | 31.77x | 63.95x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 159.07K | 0 | 0 |
| Other Non-Current Assets | -18.84K | -20.38K | -17.14K | 1.72M | 1.27M | 956.93K | 1.22M | 669.28K | 666 |
| Total Assets | 8.29M▲ 0% | 9.24M▲ 11.5% | 8.56M▼ 7.4% | 6.2M▼ 27.6% | 27.05M▲ 336.2% | 24.86M▼ 8.1% | 21.99M▼ 11.5% | 15.55M▼ 29.3% | 10.09M▼ 35.1% |
| Asset Turnover | 0.17x | 0.20x | 0.28x | 0.41x | 0.01x | 0.03x | 0.08x | 0.32x | 0.72x |
| Asset Growth % | -6.13% | 11.54% | -7.37% | -27.56% | 336.19% | -8.12% | -11.54% | -29.28% | -35.1% |
| Total Current Liabilities | 1.71M | 803.34K | 1.2M | 516.41K | 1.12M | 1.5M | 2.22M | 2.7M | 1.97M |
| Accounts Payable | 699.53K | 216.94K | 715.12K | 157.64K | 106.89K | 720.87K | 790.92K | 648.85K | 1.53M |
| Days Payables Outstanding | 538.62 | 135.98 | 383.42 | 83.53 | 48.12 | 1.09K | 4.47K | 151.23 | 221.36 |
| Short-Term Debt | 365.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 19.14K | 0 | 0 | 0 | 0 | 0 | 698.2K | 0 | 0 |
| Other Current Liabilities | 36.17K | 472.39K | 376.8K | 16.02K | 864.63K | 535.96K | 401.85K | 522.57K | 0 |
| Current Ratio | 4.83x | 8.78x | 5.59x | 8.54x | 22.96x | 15.75x | 9.20x | 5.46x | 5.07x |
| Quick Ratio | 3.47x | 8.16x | 5.13x | 6.99x | 22.69x | 15.53x | 8.82x | 4.87x | 4.17x |
| Cash Conversion Cycle | 1.33K | 273.62 | -45.86 | 386.64 | 921.62 | -279.25 | 361.45 | 321.39 | 74.8 |
| Total Non-Current Liabilities | 0 | 0 | 14.98K | 41.84K | 36.2K | 175.45K | 152.21K | 141.55K | 94.58K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 18.93K | 0 | 175.41K | 150.32K | 132.94K | 71.86K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 14.98K | 22.91K | 36.2K | 36 | 1.88K | 8.61K | 22.72K |
| Total Liabilities | 1.71M | 803.34K | 1.21M | 558.25K | 1.16M | 1.68M | 2.37M | 2.84M | 2.06M |
| Total Debt | 365.86K | 0 | 0 | 61.1K | 20.5K | 209.79K | 189.09K | 173.5K | 117.13K |
| Net Debt | -3.63M | -4.73M | -5.12M | -3.19M | -25.03M | -21.9M | -16.97M | -11.48M | -2.71M |
| Debt / Equity | 0.06x | - | - | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -342.65x | -123.47x | - | -134.32x | -608.96x | -464.08x | -369.75x | -765.72x | -731.63x |
| Total Equity | 6.57M▲ 0% | 8.44M▲ 28.4% | 7.35M▼ 12.9% | 5.64M▼ 23.2% | 25.9M▲ 358.8% | 23.18M▼ 10.5% | 19.62M▼ 15.4% | 12.71M▼ 35.2% | 8.03M▼ 36.8% |
| Equity Growth % | 33.08% | 28.36% | -12.89% | -23.22% | 358.81% | -10.49% | -15.36% | -35.21% | -36.8% |
| Book Value per Share | 2.48 | 2.53 | 2.03 | 1.28 | 4.69 | 4.07 | 3.44 | 2.23 | 1.39 |
| Total Shareholders' Equity | 6.57M | 8.44M | 7.35M | 5.64M | 25.9M | 23.18M | 19.62M | 12.71M | 8.03M |
| Common Stock | 53.63M | 58.37M | 60.29M | 62.43M | 88.36M | 88.44M | 88.44M | 88.5M | 88.87M |
| Retained Earnings | -49.53M | -52.54M | -57.24M | -57.92M | -65.93M | -68.43M | -72.06M | -78.97M | -82.48M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.47M | 2.61M | 4.3M | 1.13M | 3.47M | 3.17M | 3.24M | 3.17M | 1.64M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMRN Cash Flow Statement
Immuron Limited (IMRN) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.03M | -3.5M | -1.29M | -3.16M | -3.05M | -3.13M | -2.49M | -5.88M | -6.14M |
| Operating CF Margin % | -503.59% | -190.16% | -53.88% | -125.66% | -2089.45% | -409.33% | -137.89% | -119.93% | -84.22% |
| Operating CF Growth % | -87.31% | 50.16% | 63.3% | -146.05% | 3.76% | -2.83% | 20.55% | -136.29% | -4.37% |
| Net Income | -6.8M | -3.01M | -3.33M | -2.93M | -6.25M | -2.85M | -3.79M | -6.94M | -5.22M |
| Depreciation & Amortization | 4.92K | 5.05K | 3.78K | 44.06K | 32.57K | 26.61K | 48.66K | 0 | 49.69K |
| Stock-Based Compensation | 522.66K | 242.95K | 0 | -533.91K | 0 | 94.89K | 226.95K | 0 | 304.24K |
| Deferred Taxes | 0 | -347.31K | 0 | 610.96K | 0 | 76.11K | -842.14K | 0 | 0 |
| Other Non-Cash Items | -481.86K | -498.64K | 994.14K | -539.93K | 2.04M | -205.63K | 465.6K | 2.03M | -753.38K |
| Working Capital Changes | -793.42K | 104.36K | 1.05M | 181.26K | 1.14M | -269.92K | 1.4M | -974.81K | -521.51K |
| Change in Receivables | 7.4K | 438K | 486.55K | 641.24K | 17.18K | -337K | 226.37K | -958.47K | -557.25K |
| Change in Inventory | -280.06K | -333.64K | 188.35K | -113.64K | 716.79K | 275.61K | -776.1K | -194.28K | 480.86K |
| Change in Payables | -559.45K | -620.2K | 304.85K | -362.44K | 437.72K | 285.62K | 31.88K | 0 | 0 |
| Cash from Investing | -5.7K | -5.32K | -1.46K | -864 | -4.95K | 11.74K | -2.74M | 327.56K | -2.9M |
| Capital Expenditures | -5.7K | -6.59K | -1.46K | -864 | -4.95K | -10.05K | -7.74K | -195 | 0 |
| CapEx % of Revenue | 0.41% | 0.36% | 0.06% | 0.03% | 3.39% | 1.31% | 0.43% | 0% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | -2.73M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 1.28K | 0 | 0 | 0 | 21.79K | -2.61M | 327.76K | -2.9M |
| Cash from Financing | 8.7M | 4.35M | 1.48M | 1.17M | 19.76M | -36.26K | -35.02K | 829 | 199.75K |
| Debt Issued (Net) | 0 | -365.86K | 0 | -366.65K | 0 | -36.26K | -35.02K | -15.6K | -65.66K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 24K | 396.83K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.69M | -757.35K | 0 | -41.39K | -30.29K | 0 | 0 | -7.58K | -131.42K |
| Net Change in Cash | 1.7M▲ 0% | 732.51K▼ 57.0% | 392.46K▼ 46.4% | -1.87M▼ 576.3% | 21.8M▲ 1266.0% | -2.94M▼ 113.5% | -4.95M▼ 68.6% | -5.5M▼ 11.1% | -8.83M▼ 60.4% |
| Free Cash Flow | -7.04M▲ 0% | -3.51M▲ 50.1% | -1.29M▲ 63.3% | -3.17M▼ 145.8% | -3.05M▲ 3.6% | -3.14M▼ 3.0% | -2.5M▲ 20.6% | -5.88M▼ 135.6% | -6.14M▼ 4.4% |
| FCF Margin % | -504% | -190.52% | -53.94% | -125.69% | -2092.84% | -410.65% | -138.32% | -119.94% | -84.22% |
| FCF Growth % | -87.37% | 50.1% | 63.33% | -145.84% | 3.63% | -3% | 20.56% | -135.57% | -4.36% |
| FCF per Share | -2.66 | -1.05 | -0.36 | -0.72 | -0.55 | -0.55 | -0.44 | -1.03 | -1.06 |
| FCF Conversion (FCF/Net Income) | 1.03x | 1.16x | 0.28x | 1.08x | 0.36x | 1.10x | 0.66x | 0.85x | 1.18x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.3K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMRN Key Ratios
Immuron Limited (IMRN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -144.98% | -118.17% | -40.11% | -58.98% | -45.05% | -53.17% | -11.63% | -17.7% | -42.92% | -50.3% |
| Return on Invested Capital (ROIC) | -198.45% | -167.87% | -67.32% | -117.52% | -93.01% | -378.29% | -200.67% | -136.46% | -224.75% | -122.51% |
| Gross Margin | 69.47% | 66.05% | 68.4% | 71.49% | 72.65% | -456.22% | 68.41% | 96.42% | 68.06% | 65.39% |
| Net Margin | -706.12% | -487.33% | -163.38% | -195.04% | -116.23% | -5751.61% | -373.01% | -209.81% | -141.49% | -71.58% |
| Debt / Equity | 0.38x | 0.06x | - | - | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | -24.19x | -342.65x | -123.47x | - | -134.32x | -608.96x | -464.08x | -369.75x | -765.72x | -731.63x |
| FCF Conversion | 0.53x | 1.03x | 1.16x | 0.28x | 1.08x | 0.36x | 1.10x | 0.66x | 0.85x | 1.18x |
| Revenue Growth | -0.13% | 39.47% | 31.99% | 29.55% | 5.49% | -94.21% | 424.91% | 135.85% | 171.67% | 48.63% |
IMRN Frequently Asked Questions
Immuron Limited (IMRN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immuron Limited (IMRN) reported $10.9M in revenue for fiscal year 2025. This represents a 2139% increase from $0.5M in 2001.
Immuron Limited (IMRN) grew revenue by 48.6% over the past year. This is strong growth.
Immuron Limited (IMRN) reported a net loss of $7.9M for fiscal year 2025.
Dividend & Returns
Immuron Limited (IMRN) has a return on equity (ROE) of -50.3%. Negative ROE indicates the company is unprofitable.
Immuron Limited (IMRN) had negative free cash flow of $9.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More IMRN
Immuron Limited (IMRN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates